title: Bioresorbable Scaffolds for Coronary Artery Disease.
abstract: The purpose of this review is to present an overview of the recent evidence regarding the use of bioresorbable scaffolds in percutaneous coronary intervention.
  
  
  
  Bioresorbable scaffolds represent a potentially unique engineering solution to the problems associated with metallic stents. The Absorb everolimus-eluting bioresorbable scaffold has been the most extensively tested of this class and is currently Food and Drug Administration-approved for use in the USA. While early studies suggested that it has comparable overall efficacy as compared to drug-eluting metallic stents, they also demonstrated a significantly increased risk of stent thrombosis. Bioresorbable scaffolds may be comparable to drug-eluting stents, though associated with an increased risk of stent thrombosis. They are a nascent technology with several competitive product designs in development and continued iterative technological improvements are expected over the next several years.
authors.affiliation: Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.|Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Ashwin
authors.initials: A
authors.lastname: Nathan
authors.affiliation: Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.|Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Taisei
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.|Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Kolansky
authors.affiliation: Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.|Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Wilensky
authors.affiliation: Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Jay.Giri@uphs.upenn.edu.|Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA. Jay.Giri@uphs.upenn.edu.
authors.forename: Jay
authors.initials: J
authors.lastname: Giri
mesh_terms: D020341:Absorbable Implants; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008670:Metals / Q000009:adverse effects; D009203:Myocardial Infarction / Q000628:therapy; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D008670:Metals; D000068338:Everolimus
keywords: Bioresorbable scaffolds; Coronary artery disease; Percutaneous coronary intervention